Akero Therapeutics, Inc.
AKRO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.48 | 1.24 | 1.23 | -0.23 |
| FCF Yield | -1.11% | -2.13% | -3.42% | -3.53% |
| EV / EBITDA | -60.25 | -43.62 | -24.11 | -23.97 |
| Quality | ||||
| ROIC | -7.61% | -7.22% | -9.92% | -10.54% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.68 | 0.96 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 28.70% | -0.86% | 4.73% | -20.48% |
| Safety | ||||
| Net Debt / EBITDA | 2.64 | 2.15 | 4.42 | 3.91 |
| Interest Coverage | -69.00 | -70.09 | -65.02 | -65.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -406,215.00 | -2,270,070.00 |